About Antiverse
Antiverse is a company based in Cardiff (United Kingdom) founded in 2017 by Murat Tunaboylu and Ben Holland. Antiverse has raised $18.88 million across 7 funding rounds from investors including Syndicate Room, Development Bank of Wales and AngelHub. The company has 7 employees as of April 30, 2022. Antiverse operates in a competitive market with competitors including AbSci, LabGenius, Ordaos, immunitoAI and Enpicom, among others.
- Headquarter Cardiff, United Kingdom
- Employees 7 as on 30 Apr, 2022
- Founders Murat Tunaboylu, Ben Holland
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Antiverse Ltd
- Date of Incorporation 24 Apr, 2017
- Jurisdiction CARDIFF, WALES
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$18.88 M (USD)
in 7 rounds
-
Latest Funding Round
$9.3 M (USD), Series A
Mar 03, 2026
-
Investors
Syndicate Room
& 17 more
-
Employee Count
7
as on Apr 30, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Antiverse
Unlock access to complete
Funding Insights of Antiverse
Antiverse has successfully raised a total of $18.88M across 7 strategic funding rounds. The most recent funding activity was a Series A round of $9.3 million completed in March 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Antiverse
Antiverse has secured backing from 18 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include Syndicate Room, Development Bank of Wales and AngelHub.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Investments in technology companies are made by Kadmos Capital.
|
Locked | Locked | Locked | |
|
Venture capital firm focused on AI, healthcare, life science, B2B enterprise, and technology sectors
|
Locked | Locked | Locked |
Investor details for Antiverse
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Antiverse
Investment portfolio details for Antiverse
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Antiverse
Detailed financials for Antiverse
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Antiverse Comparisons
Peer comparison for Antiverse
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Antiverse
Antiverse operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as AbSci, LabGenius, Ordaos, immunitoAI and Enpicom, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
AI-based technology is used for recombinant protein production in therapeutics.
|
|
| Locked | Locked | Locked |
AI-driven platform for discovering and optimizing therapeutic antibodies for treatments.
|
|
| Locked | Locked | Locked |
AI accelerator provided for biomedical research and drug discovery.
|
|
| Locked | Locked | Locked |
An AI-based platform for antibody discovery and therapeutics is developed.
|
|
| Locked | Locked | Locked |
Developer of bioinformatics platform integrating data, automation, and AI for biologics
|
Detailed competitors of Antiverse
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Antiverse
Complete news archive for Antiverse
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Antiverse
Antiverse was founded in 2017 and raised its 1st funding round 1 year after it was founded.
Antiverse is headquartered in Cardiff, United Kingdom. It is registered at Cardiff, Wales, United Kingdom.
Murat Tunaboylu is the current CEO of Antiverse. They have also founded this company.
Antiverse is a funded company, having raised a total of $18.88M across 7 funding rounds to date.
As of Apr 30, 2022, the latest employee count at Antiverse is 7.
Antiverse was founded in 2017 and is headquartered in Cardiff, United Kingdom. Operations center on the biotechnology sector, where an AI-based platform is utilized for antibody drug discovery. Machine learning techniques are applied to predict antibody-antigen binding. Services include the development of antibody drug candidates, phage technology integration, 3D imaging analysis, customized data generation, sequence detection, and computational biology tools.
Antiverse's top competitors include AbSci, Ordaos and immunitoAI.
Antiverse has 18 investors. Key investors include Syndicate Room, Development Bank of Wales, AngelHub, Cambridge Angels, and i&i Bio.